Financial support: None.
Pegylated versus standard interferon plus ribavirin in chronic hepatitis C genotype 4: A systematic review and meta-analysis
Article first published online: 4 MAR 2013
© 2013 The Japan Society of Hepatology
How to Cite
Aljumah, A. A. and Murad, M. H. (2013), Pegylated versus standard interferon plus ribavirin in chronic hepatitis C genotype 4: A systematic review and meta-analysis. Hepatology Research. doi: 10.1111/hepr.12084
Conflict of interest: None.
- Article first published online: 4 MAR 2013
- Accepted manuscript online: 5 FEB 2013 06:47AM EST
- Manuscript Accepted: 29 JAN 2013
- Manuscript Revised: 23 JAN 2013
- Manuscript Received: 7 JAN 2013
- antiviral therapy;
- genotype 4;
- hepatitis C;
- pegylated interferon;
- randomized controlled trial
Treatment of hepatitis C genotype 4 (HCV-G4) with pegylated interferon (PEG IFN) has not been adequately studied and is considered to be challenging. The aim of this meta-analysis is to systematically review and evaluate the effectiveness of 48 weeks of combined PEG IFN plus ribavirin (RBV) compared to standard interferon (IFN) plus RBV. The outcome of interest is sustained virological response (SVR).
We searched for eligible randomized controlled trials (RCT) through May 2012. Random effects meta-analysis was used to pool the risk ratio (RR) of achieving SVR across trials.
Five RCT enrolling 386 patients were included. The PEG IFN/RBV group had increased likelihood of achieving SVR (RR = 1.51, 95% confidence interval [CI] = 1.08–2.10). SVR was significantly higher in PEG IFN-α-2a compared to the -α-2b group (P = 0.02). There was no statistically significant effect of ribavirin dosage on SVR (P = 0.55). The quality of evidence was moderate overall and limited by heterogeneity.
In treatment-naive patients with HCV-G4, treatment with PEG IFN plus RBV achieves higher SVR rate than treatment with IFN plus RBV.